All Oncology News

The novel ADC CRB-701 was granted FDA fast track designation for the treatment of patients with recurrent or metastatic pretreated HNSCC.

The combination of metformin, letrozole, and abemaciclib was safe and active in patients with ER-positive recurrent endometrial cancer.

The FDA approval of belzutifan in patients with pheochromocytoma or paraganglioma is a testament to the power of drug discovery in rare tumor subsets.

Paolo Ghia, MD, PhD, details the final analysis of the phase 2 CAPTIVATE study evaluating frontline ibrutinib/venetoclax in patients with CLL.

Neoadjuvant tislelizumab plus chemotherapy yielded responses in locally advanced cervical cancer.

Updated PYNNACLE data show activity of rezatapopt in TP53 Y220C–mutated solid tumors.

A new drug application for nadofaragene firadenovec in BCG-unresponsive bladder cancer has been accepted for review in Japan.

Topics presented at the conference include the tumor microenvironment, metabolic influences, immune effects, and more.

The Idylla CDx MSI Test will soon be available as a companion diagnostic for identifying patients with MSI-H CRC eligible for treatment with nivolumab.

Raludotatug deruxtecan earned FDA breakthrough designation for CDH6-expressing platinum-resistant ovarian cancers after bevacizumab treatment.

BTK inhibitors were associated with lower health care resource utilization vs other regimens in mantle cell lymphoma.

IDE397 plus sacituzumab govitecan shows preliminary efficacy in MTAP-deletion urothelial cancer.

Tarlatamab plus anti–PD-L1 as frontline maintenance shows acceptable safety and unprecedented survival in extensive-stage SCLC.

Tarlatamab plus anti–PD-L1 therapy as frontline maintenance shows acceptable safety and unprecedented survival in extensive-stage SCLC.

A roadmap shares guidelines for the safe administration of bispecific antibodies to patients with multiple myeloma in outpatient and community settings.

The top 5 OncLive TV videos of the week cover insights in lung cancer, non–muscle-invasive bladder cancer, and colorectal cancer.

The FDA has approved TAR-200 in urothelial cancer and selumetinib in pediatric NF-1–associated inoperable plexiform neurofibromas, and more.

Kelsey Pan, MD, MPH, discusses notable presentations from an OncLive Fellows Forum on Thoracic Oncology.

Trastuzumab pamirtecan improved progression-free survival in HER2-positive advanced breast cancer after prior trastuzumab and taxane-based chemotherapy.

Vanda Salutari, MD, discusses the efficacy of first-line rucaparib maintenance therapy in patients with HRD-negative high-grade, advanced ovarian cancer.

Huntsman Cancer Institute has been listed 10th among the top 75 cancer care hospitals in the US.

Frontline amivantamab plus lazertinib generated an OS benefit vs osimertinib in patients with EGFR-mutated NSCLC in the Asia cohort of the MARIPOSA trial.

The PD-L1– and VEGF-directed bispecific antibody IMM2510 proved active in patients with squamous NSCLC after prior chemotherapy and immunotherapy.

Ultrasound is cheaper, faster, and is widely available compared with MRI, but is it enough to displace the gold standard imaging tool?

The novel BTK degrader led to fast-onset responses that were maintained over time in patients with CLL/SLL.

The Shield blood-based CRC screening test demonstrated a sensitivity of 84% for detecting CRC with 90% specificity in an expanded cohort.

Ryan M. Kahn, MD, MHS, FACOG, discusses the evolution of surgical techniques and practice-changing treatments in the ovarian cancer treatment paradigm.

Supriya Gupta, MD, discussed the utility of axi-cel and liso-cel in real-world settings as second-line treatment in large B-cell lymphoma.

The NAPBC has renewed Fox Chase Cancer Center’s accreditation, making it the sixth consecutive time Fox Chase has been honored with this distinction.

The marketing authorization application submitted to the EMA for T-DXd in HER2-positive unresectable or metastatic solid tumors has been validated.